SLC29A1 and neoplasm: The reported randomized phase III study conducted by Poplin et al. highlighted a new rabbit monoclonal hENT1 antibody (clone SP120), but hENT1 tumor expression was not found to predict gemcitabine benefit in patients with treatment-naive metastatic PDAC [7].